These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30526125)

  • 1. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
    Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
    El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
    J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 4. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
    Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
    BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
    Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
    J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
    Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
    Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
    Kamstra R; Pilon D; Lefebvre P; Emond B; Joshi K
    Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
    Patel C; Emond B; Morrison L; Lafeuille MH; Lefebvre P; Lin D; Kim E; Joshi K
    Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
    Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
    Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates.
    Nuhoho S; Saad A; Saumell G; Ribes D; El Khoury AC
    Curr Med Res Opin; 2018 Apr; 34(4):601-611. PubMed ID: 29292670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
    Joshi K; Lafeuille MH; Kamstra R; Tiggelaar S; Lefebvre P; Kim E; Yue Y; Tandon N
    J Comp Eff Res; 2018 Feb; 7(2):121-133. PubMed ID: 28809128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.
    Pilon D; Amos TB; Kamstra R; Manceur AM; El Khoury AC; Lefebvre P
    Curr Med Res Opin; 2019 Jan; 35(1):41-49. PubMed ID: 30106313
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
    Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
    Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.
    Joshi K; Lin J; Lingohr-Smith M; Fu DJ
    J Med Econ; 2015; 18(8):629-36. PubMed ID: 25800457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
    Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
    Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.